Mr. Delacourt is a senior litigator and regulatory counselor with more than a decade of experience advising biotech companies WASHINGTON – (March 15, 2023) – The Biotechnology Innovation Organization (BIO) welcomes John Delacourt as Deputy General Counsel – VP Health, Regulatory, and Commercial Operations. John will work with BIO’s staff to lead legal support for commercial operations and with its membership to ensure patient access to life-saving medicines, bring down barriers to innovation, and promote policies conducive to advances in agriculture and environmental science.  John comes to BIO from another biotech trade group – the Plasma Protein Therapeutics Association (PPTA) – where he served as Chief Legal Officer & Head of Global Policy. While at PPTA, John led the association’s litigation defense and regulatory compliance efforts in both the United States and Europe. He also served as legal advisor to PPTA’s principal governing bodies, including on such issues as drug shortage preparedness, discriminatory labeling practices, and secure handling of biometric data. Prior to joining PPTA, John practiced at major law firms in Washington, D.C. and New York. He also served in senior roles at the Federal Trade Commission, including as Chief Antitrust Counsel of the FTC’s Office of Policy Planning. “John’s healthcare and compliance experience make him a welcome addition to our growing legal team,” said Chief Legal Officer Peter McHugh. “As BIO continues to address the legal challenges presented by the Inflation Reduction Act, advocate for efficient market access for innovative products, and support a favorable environment for biotech investment, we are excited to have John on our side.” John is a graduate of Georgetown University and Harvard Law School.

"The ecosystem that allows America to develop groundbreaking new medicines is extremely important to our nation and to patients who depend on biotechnology companies. The recent actions by the FDIC, the Federal Reserve, and Treasury to allow SVB depositors to have access to all of their money is a very positive development to mitigate the potential harm to companies that are innovating across healthcare, agriculture, and the bioeconomy. We will continue to monitor the situation and will work closely with regulators to ensure that companies can meet payroll and continue to fund cutting-edge science and the development of treatments and therapies that patients are relying on." Rachel King President and CEO, BIO

President Biden today unveiled details of the White House’s budget request that included drastic changes to the Medicare program, including further expanding the program’s new authority to institute price controls in Medicare. BIO Chief Advocacy Officer, Nick Shipley, made the following statement: “The President’s plan to expand Medicare price controls is another costly blow to the millions of patients depending on innovative cures, particularly those in the rare and orphan drug space. The White House hasn’t even implemented the pharmaceutical provisions in the Inflation Reduction Act, yet they are already proposing to further destabilize Medicare, slow critical investment in future research and development, stall drug innovation, and ultimately harm patients. Press reports indicate HHS wants to double the size of the price control program, without even the slightest acknowledgement about impacts on diseases like oncology or Alzheimer’s.    “These impacts are then disproportionality felt by the very small biotechnology businesses that are responsible for nearly 80% of the treatments in the clinical pipeline. These companies rely on stable investing market to stay afloat. They are also responsible for the lion's share of medical innovation, helping millions of Americans live longer and healthier lives. Without a healthy investment environment, the cures of tomorrow might never reach the patients who desperately need them. “BIO supports legislative solutions to bolster medical innovation and increase patient access to medicines. We’ve consistently advocated for patient out-of-pocket caps and a crackdown on pharmacy benefit managers – the middlemen in the drug supply chain responsible for inflating drug prices.  Much like the IRA was a gift to pharmacy benefit managers by preserving their kickback schemes, the Budget represents another missed opportunity to address one of the biggest drivers in drug pricing. “While this latest proposal is an attack…

A broad coalition of national and state agriculture and bioscience organizations have written President Biden to thank the administration for beginning technical consultations with Mexico concerning its action to ban imports of biotech corn. The groups are calling for those consultations to start without delay. “We support your administration’s request for consultations with Mexico regarding its treatment of agricultural biotechnology and denying the use of certain crop protection tools, to provide a framework and timeline to resolve this issue,” the 65 groups wrote. “We look forward to these consultations beginning promptly.” Technical consultations bring leaders from the involved countries, which now includes Canada as well, into formal discussions to resolve the dispute. If the talks are not successful, the U.S. can initiate a dispute settlement under USMCA. The organizations expressed appreciation for the administration’s efforts over several months to resolve the issue through negotiations but indicated that the results, including a revised decree that Mexico issued Feb. 13, 2023, are inadequate, and now it is time for action. The new decree, which the groups said drew a non-science based distinction between corn for food and corn for feed and industrial uses, is inconsistent with USMCA obligations. The new decree “continues to limit the use of innovative agricultural tools, extends restrictions on safe crop protection products, and enacts barriers to trade,” the groups wrote, and it “fails to establish a science- and risk-based regulatory approval process for all agricultural biotechnology products and ignores the immediate need to establish a risk assessment process for gene editing technology.” The agriculture and biotechnology groups reiterated the importance of beginning the legal process to not only resolve the dispute with Mexico but also prevent other countries from following suit. “The United States must use the dispute mechanisms afforded in…